February 6, 2026: FDA moves against non-FDA-approved GLP-1 drugs
On February 6, 2026, FDA announced it intends to take action against non-FDA-approved GLP-1 drugs. The agency's public position matters because it sharpens the line between approved brand-label discussions and injuries involving compounded, counterfeit, or otherwise non-approved products.
That action also sharpens the line between approved brand-label discussions and injuries involving compounded, counterfeit, or otherwise non-approved products.
January 13, 2026: FDA requests removal of suicidality warning language
On January 13, 2026, FDA requested removal of suicidal-behavior and ideation warning language from the obesity GLP-1 labels that still carried it, after finding no increased risk.
That change matters because older articles and screenshots may still repeat warning language that is no longer current.
December 15, 2025: the NAION MDL is created
On December 15, 2025, the JPML created MDL 3163 for GLP-1 NAION cases. That gave the sudden-vision-loss topic its own federal litigation track separate from the larger GI-injury MDL.
The split also confirms that NAION should be treated separately from diabetic retinopathy and other eye-related questions.
April 1, 2026: current MDL counts show the scale difference
The April 1, 2026 JPML report showed 3,546 pending actions in MDL 3094 and 73 in MDL 3163. The gap in size matters because it confirms that GI injury remains the dominant federal GLP-1 litigation category by volume while NAION remains smaller but now real and distinct.
Those numbers show how much larger the GI track remains while also confirming that the NAION track is real and distinct.
2025 to 2026: the current label and research picture
The current February 2026 Wegovy label remains the backbone for severe GI reactions, pregnancy timing, gallbladder disease, retinopathy monitoring, the thyroid boxed warning, and the removal of suicidality language. The current Ozempic label remains the main product source for the diabetes-facing semaglutide track.
Current ophthalmology work and active ClinicalTrials.gov listings continue to move the evidence picture as well.